Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114023 · ClinicalTrials.gov registry record
1-Year Follow up to the 1473-IMIQ Study
A clinical trial of Keratosis, sponsored by Graceway Pharmaceuticals.
- Completed
- Registry status
- 84
- Enrollment target
- 1
- Study location
NCT00114023: Completed study of Keratosis, sponsored by Graceway Pharmaceuticals.
NCT00114023 is a study of Keratosis that has completed, run by Graceway Pharmaceuticals. The registered enrollment target is 84 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00114023, a study of Keratosis, has completed, sponsored by Graceway Pharmaceuticals.
- COMPLETED
- Registry status
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 1-year follow-up study to evaluate the long-term effects in subjects who completely cleared their actinic keratosis (AK) lesions in the 1473-IMIQ study. The 1473-IMIQ study evaluated the safety and effectiveness of imiquimod 5% cream compared to a placebo cream for the treatment of AK.
Conditions Studied
Interventions
- DRUG Imiquimod 5% cream
Study Locations (1)
Arkansas
- - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2005-01 |
What the finished NCT00114023 record still lists
NCT00114023 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 84 participants, a relatively small participant target.
The record links to 1 condition, with Keratosis appearing as the primary indexed condition, and to 1 intervention - of which Imiquimod 5% cream is the first listed.
NCT00114023 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT00114023 about?
NCT00114023 is a clinical study titled "1-Year Follow up to the 1473-IMIQ Study". This is a 1-year follow-up study to evaluate the long-term effects in subjects who completely cleared their actinic keratosis (AK) lesions in the 1473-IMIQ study. The 1473-IMIQ study evaluated the safety and effectiveness of imiquimod 5% cream compared to a placebo cream for the treatment of AK.
What is the current status of trial NCT00114023?
This trial is currently completed. The enrollment target is 84 participants. The study started on 2005-01.
What conditions does trial NCT00114023 study?
This clinical trial studies the following conditions: Keratosis.
What interventions are being tested in trial NCT00114023?
The interventions under investigation include: Imiquimod 5% cream (DRUG).
Who is sponsoring clinical trial NCT00114023?
This trial is sponsored by Graceway Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00114023 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia